SEP
EXAS

Signature Equity Partners’s Exact Sciences EXAS Stock Holding History

Signature Equity Partners’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9
Closed -$914 – 1580
2025
Q4 		$914 Buy
+9
New +$723 ﹤0.01% 1407

Other funds holding EXAS

VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.16B AUM 28.78% 1-Year Est. Return
PWMAG
Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.68B AUM 31.18% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return
BC
Broadwater Capital Boston, Massachusetts $138M AUM 28.86% 1-Year Est. Return

Signature Equity Partners's EXAS Position: Q1 2026 in Review

Signature Equity Partners sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 9 shares — an estimated $914 sold.

Signature Equity Partners first reported a position in EXAS in Q4 2025 and held it in 1 quarter. The position peaked at $914 in Q4 2025. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Signature Equity Partners reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Signature Equity Partners sold 9 Exact Sciences shares in Q1 2026, an estimated $914.
  • Signature Equity Partners first reported a position in Exact Sciences in Q4 2025 and held it in 1 quarter.
  • Signature Equity Partners's Exact Sciences position peaked at $914 in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Signature Equity Partners's 13F filing for Q1 2026, filed 13 May 2026.